Hikma finished 2021 on a strong note, with encouraging sales growth across segments. However, the 2022 outlook has come in below our expectations, with various issues in all the major businesses and/or geographies. Nevertheless, as these are only transient concerns, the firm’s investment attractiveness remains intact. Although, some moderation of the forecast seems inevitable.
25 Feb 2022
Weak outlook scars strong finish to 2021
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Weak outlook scars strong finish to 2021
Hikma Pharmaceuticals Plc (HIK:LON) | 1,788 -214.6 (-0.7%) | Mkt Cap: 3,967m
- Published:
25 Feb 2022 -
Author:
Amandeep Goyal -
Pages:
4
Hikma finished 2021 on a strong note, with encouraging sales growth across segments. However, the 2022 outlook has come in below our expectations, with various issues in all the major businesses and/or geographies. Nevertheless, as these are only transient concerns, the firm’s investment attractiveness remains intact. Although, some moderation of the forecast seems inevitable.